See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use on the NHS as they are too expensive to justify.

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST ...

The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use ...

Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for b ...

Content by Health System. June is Alzheimer’s and Brain Awareness Month, which means there’s no better time to focus on your ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

Reimagining Alzheimer's care in Canada is not just important for the system—it is imperative for all Canadians. We owe it to those affected to provide the dignity and quality of life they deserve. The ...

So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...

A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended production and ...